This series of Inflammation Expert Opinions is aimed to provide different perspectives and opinions from experts commenting on potential implications from recent research targeting inflammation in cardiovascular disease. More to come...
Inflammation Expert Opinions Prof. Wolfgang Koenig: Die CANTOS Studie belegt dass inflammatorische Prozesse eine kausale Rolle in der Atherogenese spielen. Inhibition der Inflammation führt zu einer weiteren Reduktion des kardiovaskulären Risikos ohne Beeinflussung des Lipidstatus.
Inflammation Expert Opinions Prof. Wolfgang Koenig states that the CANTOS trial shows that inflammation plays a causal role in the atherogenic process. Blocking this inflammation may be an additional treatment option beyond lipid lowering for CV risk reduction.
Inflammation Expert Opinions Lina Badimon explains why blocking inflammation may have significant clinical benefit, as inflammation is important in plaque formation. The results of CANTOS can be the dawn of a new era of CV prevention.
Inflammation Expert Opinions Erik Stroes summarizes the results from CANTOS and states that for daily clinical practice, it is important to select the major factors contributing to CV risk
Inflammation Expert Opinions Filippo Crea riflette su una pubblicazione del 1994, introducendo l’ ipotesi sull’infiammazione e spiega come lo studio CANTOS confermi tale ipotesi. La sfida ora è individuare i pazienti che trarranno beneficio da questo trattamento.
Inflammation Expert Opinions Prof Filippo Crea reflects on a publication from 1994, introducing the inflammatory hypothesis, and explains how the CANTOS trial confirms this hypothesis. The challenge is now to identify patients who will benefit from this treatment.
Inflammation Expert Opinions Philippe Gabriel Steg reflects on the CANTOS trial results that confirm the long-standing hypothesis that inflammation plays a role in CV events and he considers which questions remain to be answered before broad clinical application of this concept.
Inflammation Expert Opinions Paul Ridker and Peter Libby look back at the evolution of their research efforts on the role of inflammation in CV risk, and how they saw their hypothesis confirmed in the CANTOS trial.